Clindamycin Vaginal and Berotralstat: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Berotralstat
Clindamycin Vaginal
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased CYP3A4 substrate exposure and an increased CYP3A4 substrate-related adverse reactions
Interaction Deep Dive
Concomitant use of berotralstat 150 mg (a moderate CYP3A4 inhibitor) and a CYP3A4 substrate with a narrow therapeutic index may increase CYP3A4 substrate exposure and may increase the risk of adverse reactions associated with the substrates. Monitor appropriately and titrate the dose as required1.
Why it happens (mechanism)
Inhibition of CYP3A4-substrate metabolism by berotralstat
Common questions
Can I take Clindamycin Vaginal and Berotralstat together?
Increased CYP3A4 substrate exposure and an increased CYP3A4 substrate-related adverse reactions Always confirm with your pharmacist or prescriber before making any change.
How serious is the Clindamycin Vaginal and Berotralstat interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Clindamycin Vaginal or Berotralstat need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: ORLADEYO® oral capsules, oral pellets, berotralstat oral capsules, oral pellets. BioCryst Pharmaceuticals Inc (per manufacturer), Durham, NC, 2025. DailyMed
Keep reading about Berotralstat
Keep reading about Clindamycin Vaginal
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist